Skip to main content
. 2019 Apr 12;10:718. doi: 10.3389/fmicb.2019.00718

Table 1.

Inhibition of ZIKV replication with ATA.

ZIKV strain Drug Treatment Hours Cells CC50 (μM)1 IC50 (μM)2 SI3
Paraiba/2015 ATA Post 36 Vero >1,000 13.87 ± 1.09 >72.10
Paraiba/2015 ATA Post 36 A549 >1,000 33.33 ± 1.13 >26.26
Paraiba/2015 ARB Post 36 Vero 74.71 ± 1.09 18.19 ± 1.16 4.11
Paraiba/2015 ARB Post 36 A549 114.6 ± 1.08 51.87 ± 1.08 2.21
Uganda/1947 ATA Post 48 Vero >1,000 15.07 ± 1.19 >66.35
Nigeria/1968 ATA Post 60 Vero >1,000 15.97 ± 1.02 >62.62
Puerto Rico/2015 ATA Post 48 Vero >1,000 17.55 ± 1.16 >56.98
French Polynesia/2013 ATA Post 48 Vero >1,000 13.92 ± 1.01 >76.80
Brazil/2015 ATA Pre 12 Vero >1,000 14.33 ± 1.06 >69.78
Brazil/2015 ATA Pre 24 Vero >1,000 13.18 ± 1.05 >75.87
Brazil/2015 ATA Pre 48 Vero >1,000 12.59 ± 1.02 >79.42
Brazil/2015 ATA Pre 72 Vero >1,000 10.50 ± 1.05 >95.24

1Median cytotoxicity concentration 50 (CC50). 2Median inhibitory concentration 50 (IC50). 3SI (Selective index) = CC50/IC50. For ATA, the SI was calculated considering a CC50 of 1,000 μM.